大洋生物(003017.SZ):2021年度擬從銀行融資金額不超3億元
格隆匯 2 月 7日丨大洋生物(003017.SZ)公佈,公司於2021年2月5日召開的第四屆董事會第二十三次會議及第四屆監事會第十五次會議審議通過了《關於公司與子公司向銀行融資及公司與關聯方為子公司提供擔保的議案》,同意公司及子公司2021年度擬從銀行融資金額不超過3億元人民幣。公司及子公司以自有資產(包括但不限於房產、土地、機器設備等)提供擔保;同時,公司為子公司浙江舜躍生物科技有限公司、福建舜躍科技股份有限公司、建德市恆洋化工有限公司(以下分別簡稱“浙江舜躍”、“福建舜躍”、“恆洋化工”)提供連帶責任擔保,額度合計不超過2億元,其中公司及關聯方各自為子公司浙江舜躍、恆洋化工提供連帶責任擔保額度合計不超過5800萬元。該事項尚需提交公司2021年第一次臨時股東大會審議,
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.